We would like to emphasize that EerI or another potent VCP inhibitor may have added potential as a novel cancer therapeutic over existing proteostasis and HDAC (histone deacetylase) inhibitors [such as the FDA-approved drugs bortezomib/PS-341 [46] and SAHA [47]] as its targets upstream VCP-retrograde translocation step prior to proteasomal and HDAC6 mediated protein processing as we recently discussed [9], [35]. The gene discussed is HDAC9; the disease is cancer.